"The audit of our API Cuernavaca plant in Mexico by the USFDA has been completed with zero observations," Dr Reddy's Laboratories (DRL) said in a BSE filing.
The stock was trading 0.96 per cent lower at Rs 447 on the BSE.
Disclaimer: No Business Standard Journalist was involved in creation of this content